Follow us on Twitter
This page is updated frequently with new Elan-related patent applications. Subscribe to the Elan RSS feed to automatically get the update: related Elan RSS feeds. RSS updates for this page: Elan RSS
Chloride, bromide and iodide scintillators with european doping
|| List of recent Elan-related patents
|Methods and compositions for diagnosis and prognosis of renal injury and renal failure|
The present invention relates to methods and compositions for monitoring, diagnosis, prognosis, and determination of treatment regimens in subjects suffering from or suspected of having a renal injury. In particular, the invention relates to using a one or more assays configured to detect a kidney injury marker selected from the group consisting of growth/differentiation factor 2, catalase, vascular endothelial growth factor c, and melanoma-derived growth regulatory protein as diagnostic and prognostic biomarkers in renal injuries..
|Chloride, bromide and iodide scintillators with european doping|
A halide scintillator material is disclosed where the halide may comprise chloride, bromide or iodide. The material is single-crystalline and has a composition of the general formula abx3 where a is an alkali, b is an alkali earth and x is a halide which general composition was investigated.
|Melanin production inhibitor|
Disclosed is a melanin production inhibitor which has an excellent inhibitory activity on the production of melanin and is highly safe. The melanin production inhibitor is represented by general formula (1) (excluding clotrimazole) and/or a pharmacologically acceptable salt thereof.
|Series of skin whitening (lightening) compounds|
The present invention is directed to inhibitors of tyrosinase, pharmaceutical compositions comprising such tyrosinase inhibitors, and methods of making and using the same. Specifically, included in the present invention are compositions of matter comprised of at least one 2,4-dihydroxybenzene analog, which inhibit the activity of tyrosinase and which inhibit the overproduction of melanin..
|Methods for producing melanin and inorganic fertilizer from fermentation leachates|
Melanin or inorganic fertilizers are produced from fermentation leachates or from low-cost nutrient-rich solutions. The method for producing the melanin or inorganic fertilizer comprises repetitive trophic cycling in the controlled conditions of primary and secondary bioreactors.
|Melanocortin receptor-specific heptapeptides|
Or a pharmaceutically acceptable salt thereof, where z, xaa1, xaa2, xaa3, xaa4, xaa5, xaa6, xaa7 and y are as defined in the specification, compositions and formulations including the peptides of the foregoing formula, and methods of preventing, ameliorating or treating melanocortin receptor-mediated diseases, indications, conditions and syndromes.. .
|Cell phone case with templates for photograph collage or melange|
A protective case for an electronic device comprises a main frame with clear display panel as collage template to be able to display photographs and/or artworks. In one embodiment, the clear display panel is removable and interchangeable; so that the user has the flexibility of changing to a different display panel which serves as the collage template, therefore, the user is able to display their favorite photographs and/or artworks at their own convenience..
|Composition containing paper mulberry extracts|
Disclosed is a use of a composition containing a paper mulberry extract, and more particularly to a use of a composition containing, as an active ingredient, a paper mulberry extract in enhancement of skin moisturization, inhibition of skin aging, alleviation of inflammation, antibacterial activity, pore size reduction, sebum control, skin complexion improvement, decomposition of subcutaneous fat, stimulation of melanin synthesis, and gray hair prevention.. .
|Probes, methods of making probes, and methods of use|
Embodiments of the present disclosure provide for water soluble polyethylene glycol (peg)-polymeric melanin (peg-melanin) nanoparticles, methods of using the peg-melanin nanoparticle, methods of making the peg-melanin nanoparticle, methods of imaging a diseases or condition (e.g., pre-cancerous tissue, cancer, or a tumor), and the like. Embodiments of the present disclosure can be used in multimodal imaging (e.g., photoacoustic, nuclear, magnetic, fluorescent, and the like)..
|Label removal solution for low temperature and low alkaline conditions|
According to the invention, the compositions and methods provide for the complete removal of synthetic glues or adhesives from a plurality of surfaces through the use of amide solvents in combination with surfactants, chelants, acidulants and/or additional bottle wash additives. Beneficially, the compositions and methods are suitable for use at lower temperatures, including below 35° c., and lower ph conditions, including from 5 to 10, from 6 to 9, and from 6 to 8, in comparison to conventional caustic-based adhesive removal compositions..
|Combinatorial methods and compositions for treatment of melanoma|
The invention relates to combining targeted therapies with selected chemotherapeutics for the treatment of melanoma. The invention provides a method for inducing apoptosis in a melanoma tumor cell by reducing akt3 activity, a method for inducing apoptosis in a melanoma tumor cell comprising contacting a melanoma tumor cell with an agent that reduces akt3 activity to restore normal apoptotic sensitivity to a melanoma tumor cell, allowing a lower concentration of chemotherapeutic agents resulting in decreased toxicity to a patient.
|Method to modulate pigmentation process in the melanocytes of skin|
The invention describes a method to modulate melanosome maturation process in melanocytes. Further, it describes a method to reversibly alter the process of pigmentation in the human epidermal skin.
|Compositions and methods for treating cancer|
The instant invention provides a method of treating a cancer, selected from the group consisting of breast cancer, melanoma, colorectal cancer, non-small cell lung cancer and ovarian cancer, by administering a combination of a wee1 inhibitor and a chk1 inhibitor, wherein the wee1 inhibitor is mk-1775 or a pharmaceutically acceptable salt thereof, or mk-3652 or a pharmaceutically acceptable salt thereof, and the chk1 inhibitor is mk-8776 or a pharmaceutically acceptable salt thereof, or sch900444 or a pharmaceutically acceptable salt thereof.. .
|Composition for targeting dendritic cells|
The present invention relates to a composition for targeting dendritic cells. In particular, the present invention relates to a composition comprising: a) one or more antigens; b) an anti-dc-sign immunoglobulin single variable domain; and c) a carrier which carries a) and b).
|Therapeutic combinations and methods of treating melanoma|
The invention provides therapeutic combinations of anti-etbr antibodies and map kinase inhibitors and methods of using the same to treat melanoma.. .
|Sirna molecule for inhibiting growth of melanin and application thereof|
Provided is a double-chain sirna molecule targeting a microphthalmia-associated transcription factor mitf coding gene. A sense strand of the sirna molecule has a sequence of seq id no: 3 and an anti-sense strand has a sequence of seq id no: 4, and the anti-sense strand specifically binds to mrna of the mitf coding gene, to degrade the mrna, thereby reducing the systhesis of melanin.
|Compositions and methods for screening and treatment of sturge-weber syndrome, klippel-trenaunay-weber syndrome, and port-wine stains (pwss)|
Compositions and methods for treatment of sturge-weber syndrome, klippel-trenaunay-weber syndrome, port-wine stains and related neurocutaneous disorders are provided. Cell lines having the somatic mutation gnaq p.arg183gln amino acid substitution, which was found to be the cause of port-wine stains (prevalence 1 in 300) and sturge-weber syndrome are also provided.
This invention relates to a process for inhibiting scaling in a subterranean oil or gas producing formation, comprising adding to the formation a composition comprising a metal chelant, a scale inhibitor and divalent metal cations, wherein the stability constant of the metal chelant—metal cation chelate at ambient temperature is equal to or higher than the stability constant of the chelate formed from the metal cations and the scale inhibitor, and wherein the solubility of the chelate formed from the metal cations and the scale inhibitor decreases with increasing temperature.. .
|Method of treating melanocortin-4 receptor-associated disorders in heterozygous carriers|
A method of treating a disorder in a subject. The method comprises administering to said subject an effective amount of an agonist of the melanocortin-4 receptor (mc4r).
|Cosmetic compositions and methods for inhibiting melanin synthesis|
A cosmetic composition suitable for topical application, for example, is provided. In some examples, the cosmetic composition may include batyl alcohol, undecylenoyl phenylalanine, hexyldecanol, and bisabolol.
|Methods, systems, and apparatus for reducing the frequency and/or severity of photophobic responses or for modulating circadian cycles|
An optical filter may reduce the frequency and/or severity of photophobic responses or for modulating circadian cycles by controlling light exposure to cells in the human eye in certain wavelengths, such as 480 nm and 590 nm, and a visual spectral response of the human eye. The optical filter may disrupt the isomerization of melanopsin in the human eye reducing the availability of the active isoform, whereas the attenuation of light weighted across the action potential spectrum of the active isoform attenuates the phototransduction cascade leading to photophobic responses.
|Skin lightener in phototherapy|
The invention relates, inter alia, to melanin synthesis inhibitors for use in treating skin illnesses, wherein the skin is additionally irradiated with an artificial radiation source. The invention further relates to cosmetic treatments..
|Herbicidal compositions comprising oxyfluorfen and haloxyfop|
An herbicidal composition containing (a) oxyfluorfen and (b) haloxyfop or an agriculturally acceptable ester or salt thereof provides control of undesirable vegetation, e.g., in crops, including but not limited to direct-seeded, water-seeded and transplanted rice, wheat, barley, oats, rye, sorghum, corn/maize, cotton, pastures, grasslands, rangelands, fallowland, turf, tree and vine orchards, including, but not limited to, citrus, grapes and tree nuts, aquatics, vegetables (e.g., onions, shallots, peppers, tomatoes, artichokes, cole crops, guava, papaya and strawberries), industrial vegetation management, deciduous trees, conifers, perennial crops and plantation crops (including, but not limited to, coffee and palm oil) and rights of way.. .
|Natural and synthetic compounds for treating cancer and other diseases|
This invention provides a method of synthesizing new active compounds for pharmaceutical uses including cancer treatment, wherein the cancers comprise breast, leukocytic, liver, ovarian, bladder, prostatic, skin, bone, brain, leukemia, lung, colon, cns, melanoma, renal, cervical, esophageal, testicular, spleenic, kidney, lymphatic, pancreatic, stomach and thyroid cancers. This invention is an anti-adhesion therapy which uses the compound as a mediator or inhibitor of adhesion proteins and angiopoietins.
|Ige anti-hmw-maa antibody|
In one aspect, there is provided an antibody or a functional fragment thereof, wherein the antibody or functional fragment thereof is capable of binding specifically to high molecular weight melanoma associated antigen (hmw-maa), and binding to an fcε receptor.. .
|Fragments of p97 and uses thereof|
Provided are fragments of human p97 (melanotransferrin) polypeptides having blood-brain barrier (bbb) transport activity, including variants and combinations thereof, conjugates comprising said p97 fragments, and related methods of use thereof, for instance, to facilitate delivery of therapeutic or diagnostic agents across the bbb.. .
|Integrin-blocking polypeptides and uses thereof|
A series of integrin blockers that present strong angiogenesis inhibiting performance, high integrin affinity and integrin-bonding capacity is provided. This series of integrin blockers can be adopted in treatment of solid tumors and rheumatoid arthritis.
|Antigen presenting cancer vaccine|
The disclosure provides reagents, methods, and kits, for treating melanoma. The reagent encompasses interferon-gamma (ifn-gamma) responsive melanoma cells, where the cells are autophagic and non-apoptotic melanoma cells, and where the cells express mhc class if.
|Compositions containing purine and pyrimidine nucleosides, peptides, and manganese and their uses|
The invention provides methods of producing vaccines directed against methicillin-resistant staphylococcus aureus (mrsa) or venezuelan equine encephalitis virus (veev), with the methods comprising culturing, harvesting and/or suspending the mrsa or veev in the presence of a radiation-protective composition and irradiating the mrsa with a dose of radiation sufficient to render the mrsa or veev replication-deficient and/or non-infective. The radiation-protective compositions used in the methods of the present invention comprise at least one nucleoside, at least one antioxidant and at least one small peptide..
|Methods, agents and peptides for inhibiting matrix metalloproteinase-2 signaling|
Screening assays and methods of using same for screening to identify modulator agents or compounds that affect matrix metalloproteinase-2 (mmp-2) mediated activation of toll-like receptor-2 (tlr-2) are described herein. Pharmaceutical and immunogenic compositions comprising agents or compounds that modulate mmp-2 mediated activation of tlr-2 are also encompassed.
|Method for inhibiting inflammation and reducing melanophilin expression with glycine derivatives and the composition thereof|
This invention discloses method for inhibiting inflammation and reducing melanophilin expression with glycine derivatives and the composition thereof. The mentioned glycine derivatives can not only efficiently inhibit skin inflammation, but also can present significant melanophilin expression reduction.
|Treatment of cancer with dihydropyrazino-pyrazines|
Provided herein are methods for treating or preventing head and neck squamous cell carcinoma characterized by deletion of chromosome 11q22 or loss of ataxia telangiectasia mutated expression, comprising administering an effective amount of a dihydropyrazino-pyrazine to a patient having head and neck squamous cell carcinoma characterized by deletion of chromosome 11q22 or loss of ataxia telangiectasia mutated expression.. .
|Use of chelants in formate-based solutions to dissolve residual filtercakes in subterranean wells|
A wellbore fluid for dissolving a filtercake includes a chelating agent and an aqueous solution of carboxylate salt. The concentration of the chelating agent is up to 50 percent volume per volume (v/v) in the aqueous solution of carboxylate salt.
The presently disclosed subject matter provides methods of characterizing a melanoma in a subject by measuring amounts of one or more rnas, mirnas, and/or polypeptides present in cancer-derived microvesicles isolated from a biological sample from the subject.. .
|Antigen presenting cancer vaccine with gamma interferon|
The disclosure provides reagents, methods, and kits, for treating melanoma. The reagent encompasses interferon-gamma (ifn-gamma) responsive melanoma cells, where the cells are autophagic and non-apoptotic melanoma cells, and where the cells express mhc.
|Method for treating neurodegeneration using a p38mapk inhibitor|
Ataxia-telangiectasia (a-t) is a progressive degenerative disorder that results in major neurological disability. In a-t patients, necropsy has revealed atrophy of all cerebellar cortical layers with extensive purkinje and granular cell loss.
|Gene signature for the prediction of nf-kappab activity|
Methods for predicting nf-kappab (nf-kb) activity in a tumor, and more particularly to methods for predicting survival and therapeutic outcome, and selecting therapy in subjects with tumors, e.g., adenocarcinomas, e.g., lung adenocarcinomas and melanomas.. .
|Suppression of neuroendocrine diseases|
The present invention relates to a method for suppressing neuroendocrine disease. The therapy employs use of a non-cytotoxic protease, which is targeted to a neuroendocrine tumour cell, preferably via a somatostatin or cortistatin receptor, a ghrh receptor, a ghrelin receptor, a bombesin receptor, a urotensin receptor a melanin-concentrating hormone receptor 1; a kiss-1 receptor or a prolactin-releasing peptide receptor.
|Induction of thyroid iodide-handling gene expression in human cancers|
Dual suppression of the map kinase and pi3k/akt pathways showed synergistic or greatly enhanced anti-melanoma cell effects, compared to suppression of a single pathway, including the inhibition of cell proliferation, transformation and invasion, induction of g0/g1 cell cycle arrest and, importantly, cell apoptosis. Remarkably, suppression of either pathway induces the expression of thyroid iodide-handling genes and dual suppression of the two pathways synergistically and robustly induces expression of these genes, accompanied by uptake of radioiodine in the cells.
|Transdermal propranolol patch for treatment of malignant melanoma|
A transdermal d propranolol or racemic propranolol patch for use as an adjunct to surgery in the treatment of malignant melanoma and/or tattoo related applications are herein disclosed.. .
Popular terms: [SEARCH]
Elan topics: Folic Acid, Carbon Dioxide, Antibodies, Immune Response, High Energy, Inorganic Compounds, Electrolysis, Semiconductor Material, Semiconductor, Hydrogen Production From Water, Female Sexual Dysfunction, Dysfunction, Sexual Dysfunction, Mammography, Radiograph
Follow us on Twitter
This listing is a sample listing of patent applications related to Elan for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Elan with additional patents listed. Browse our RSS directory or Search for other possible listings.